COURT-RULING ·Filed Mar 30, 2026
Court ruling (district)
Actionable Insight • Neutral
Monitor for subsequent filings or docket updates in this case for material developments; no immediate financial or operational impact can be assessed from current information.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60Entry
$242.34
T+0 close · Mar 30, 2026 · via day close
Latest settled
−0.55%
T+60 · $241.00
Vs SPY
−16.58%
α at T+60
Horizons
All settled
through T+60
- T+0 · Mar 30 $242.34entry
- T+1 · 8mo ago +0.84%α −2.05% · $244.38
- T+5 · 7mo ago −1.65%α −5.96% · $238.33
- T+20 · 7mo ago −6.06%α −18.66% · $227.65
- T+60 · 5mo ago −0.55%α −16.58% · $241.00
Price Chart
REPLAYWatch the reaction play outLoading chart...
How similar events traded
Executive Summary
Analysis based on filing metadata only, document content was unavailable
Court Ruling Details
Court
United States District Court for the District of New Jersey
Court Level
District
Case Type
other
Ruling Type
other
Outcome
NULL
Precedent Risk
LOW
Key Facts
- Case: Snyder et al v. Janssen Pharmaceuticals, Inc. et al
- Filed in United States District Court for the District of New Jersey on 2026-03-30
- Janssen Pharmaceuticals, Inc. is a subsidiary of Johnson & Johnson (JNJ)
Financial Impact
Unknown, no financial details available in provided documents
Risk Factors
- Potential for future adverse rulings if the case proceeds on product liability or marketing claims, which are common in pharmaceutical litigation
- Precedent risk if this case evolves into a class action or involves off-label promotion or opioid-related allegations
Market Snapshot
Price
$242.00
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (32 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-6k5omeby-JNJ |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
Showing 10 of 21
US Market Status
Market Closed · Opens Wed (11h 2m)
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers